Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1981 1
1983 3
1992 1
1996 1
1997 1
1998 1
1999 1
2002 1
2004 1
2006 1
2007 3
2008 1
2009 1
2012 1
2013 1
2016 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults.
Bassan R, Lerede T, Barbui T. Bassan R, et al. Haematologica. 1996 Jan-Feb;81(1):20-36. Haematologica. 1996. PMID: 8900848 Review.
Here we review recurrence mechanisms and treatment possibilities in order to identify the most appropriate clinical conduct. Choice of retreatment drugs and their dosages, related or unrelated donor bone marrow transplants, autologous peripheral blood stem cell transplants …
Here we review recurrence mechanisms and treatment possibilities in order to identify the most appropriate clinical conduct. Choice o …
Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse.
Garay G, Milone J, Dibar E, Pavlovsky S, Kvicala R, Sackmann Muriel F, Montres Varela D, Eppinger-Helft M. Garay G, et al. Cancer Chemother Pharmacol. 1983;10(3):224-6. doi: 10.1007/BF00255770. Cancer Chemother Pharmacol. 1983. PMID: 6345018 Clinical Trial.
Patients with resistant or recurrent acute lymphoblastic leukemia were treated with vindesine 3 mg/m2/IV weekly X 4, daunomycin 25 mg/m2/IV weekly X 4, and prednisone 40 mg/m2/PO daily X 28. ...
Patients with resistant or recurrent acute lymphoblastic leukemia were treated with vindesine 3 mg/m2/IV weekly …
Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Tomblyn MB, et al. J Clin Oncol. 2009 Aug 1;27(22):3634-41. doi: 10.1200/JCO.2008.20.2960. Epub 2009 Jul 6. J Clin Oncol. 2009. PMID: 19581540 Free PMC article.
PURPOSE: Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care. ...
PURPOSE: Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemi …
Response of recurrent acute lymphoblastic leukemia to glucocorticoids: serial studies of receptor content, in vivo cytokinetic changes and clinical responses.
Pui CH, Costlow ME, Dahl GV, Rivera G, Murphy SB. Pui CH, et al. Leuk Res. 1983;7(6):747-53. doi: 10.1016/0145-2126(83)90068-1. Leuk Res. 1983. PMID: 6582341
The sensitivity of relapsed acute lymphoblastic leukemia (ALL) to treatment with steroids was assessed by measuring bone marrow blast, whole-cell glucocorticoid receptor (GR) levels and serial cytokinetic and clinical responses to steroids, both as single agents and in com …
The sensitivity of relapsed acute lymphoblastic leukemia (ALL) to treatment with steroids was assessed by measuring bone marrow blast, whole …
Recurrent acute lymphoblastic leukemia presenting in the lacrimal gland.
Cardone S, Yen MT, Chévez-Barrios P, Foroozan R, Yen KG. Cardone S, et al. Ophthalmic Plast Reconstr Surg. 2006 Jan-Feb;22(1):56-7. doi: 10.1097/01.iop.0000192644.97365.51. Ophthalmic Plast Reconstr Surg. 2006. PMID: 16418669
The patient underwent an incisional biopsy of the lacrimal gland that showed atypical lymphocytes consistent with recurrent acute lymphoblastic leukemia. The lacrimal gland is a rare extramedullary site for recurrence of this disease....
The patient underwent an incisional biopsy of the lacrimal gland that showed atypical lymphocytes consistent with recurrent acute …
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI. Hawkins DS, et al. Clin Cancer Res. 2004 Aug 15;10(16):5335-41. doi: 10.1158/1078-0432.CCR-04-0222. Clin Cancer Res. 2004. PMID: 15328169
Incorporation of intensive PEG-ASNase in future trials for recurrent acute lymphoblastic leukemia is warranted....
Incorporation of intensive PEG-ASNase in future trials for recurrent acute lymphoblastic leukemia is warranted.. …
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Aguayo A, et al. Cancer. 1999 Oct 1;86(7):1203-9. doi: 10.1002/(sici)1097-0142(19991001)86:7<1203::aid-cncr15>3.0.co;2-3. Cancer. 1999. PMID: 10506705 Clinical Trial.
A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct properties including a longer half-life and less immunogenic properties. METHODS: Patients with refractory or re …
A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-as …
Treatment of acute lymphoblastic leukemia in relapse: efficacy of a four-drug reinduction regimen.
Poplack DG, Reaman GH, Wesley R. Poplack DG, et al. Cancer Treat Rep. 1981;65 Suppl 4:93-6. Cancer Treat Rep. 1981. PMID: 6955015
These encouraging results underscore the efficacy of the four-drug regimen and emphasize the necessity for intensive treatment of recurrent acute lymphoblastic leukemia....
These encouraging results underscore the efficacy of the four-drug regimen and emphasize the necessity for intensive treatment of recurre …
22 results